FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA” with biopharma leaders attending BIO in Boston.

FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA”—one that would decide on drug applications much faster, ...

Noetik will use its multimodal AI models to identify which patients will most likely benefit from Agenus’s lead ...

MICB and NOTCH4 were expressed in fibroblasts and endothelial cells, two cell types that play central roles in fibrosis and vasculopathy.

Researchers say using physically patterned surfaces applied to existing device materials would reduce barriers to commercial application.

RNA-seq and spatial transcriptomics showed immune cell subsets that drive kidney and lung complications in systemic sclerosis patients.

An independent jury of experts will evaluate entries based on scientific merit, feasibility, and potential patient impact.

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

Advances are occurring in spectroscopy, reducing the challenges of rapid signal saturation and the need for extensive sample prep.

By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more accurate.